CN101947310A - 促肾上腺皮质激素类似物以及相关方法 - Google Patents

促肾上腺皮质激素类似物以及相关方法 Download PDF

Info

Publication number
CN101947310A
CN101947310A CN2010102535012A CN201010253501A CN101947310A CN 101947310 A CN101947310 A CN 101947310A CN 2010102535012 A CN2010102535012 A CN 2010102535012A CN 201010253501 A CN201010253501 A CN 201010253501A CN 101947310 A CN101947310 A CN 101947310A
Authority
CN
China
Prior art keywords
acth
ala
lys
arg
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010102535012A
Other languages
English (en)
Chinese (zh)
Inventor
M·B·布伦南
R·M·多里斯
C·哈斯克尔-吕瓦诺
U·H·霍切格施文德
J·I·科斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Denver
Oklahoma Medical Research Foundation
University of Florida
Original Assignee
University of Denver
Oklahoma Medical Research Foundation
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Denver, Oklahoma Medical Research Foundation, University of Florida filed Critical University of Denver
Publication of CN101947310A publication Critical patent/CN101947310A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2010102535012A 2004-10-27 2005-10-27 促肾上腺皮质激素类似物以及相关方法 Pending CN101947310A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62243604P 2004-10-27 2004-10-27
US60/622,436 2004-10-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2005800424277A Division CN101189022B (zh) 2004-10-27 2005-10-27 促肾上腺皮质激素类似物以及相关方法

Publications (1)

Publication Number Publication Date
CN101947310A true CN101947310A (zh) 2011-01-19

Family

ID=36336951

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010102535012A Pending CN101947310A (zh) 2004-10-27 2005-10-27 促肾上腺皮质激素类似物以及相关方法
CN2005800424277A Expired - Fee Related CN101189022B (zh) 2004-10-27 2005-10-27 促肾上腺皮质激素类似物以及相关方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2005800424277A Expired - Fee Related CN101189022B (zh) 2004-10-27 2005-10-27 促肾上腺皮质激素类似物以及相关方法

Country Status (13)

Country Link
US (4) US7919577B2 (enExample)
EP (2) EP2446894A3 (enExample)
JP (2) JP2008518026A (enExample)
KR (3) KR101058467B1 (enExample)
CN (2) CN101947310A (enExample)
AU (2) AU2005305157B2 (enExample)
CA (1) CA2584221A1 (enExample)
IL (1) IL182818A0 (enExample)
MX (1) MX2007004676A (enExample)
NZ (1) NZ554559A (enExample)
RU (2) RU2407751C2 (enExample)
SG (1) SG156680A1 (enExample)
WO (1) WO2006052468A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104277105A (zh) * 2013-07-12 2015-01-14 国家纳米科学中心 抑制β淀粉样蛋白聚集和毒性的多肽抑制剂及其应用
CN105669856A (zh) * 2016-02-13 2016-06-15 王大勇 一种基因重组长效人促肾上腺皮质激素及其制备方法
CN106478771A (zh) * 2016-10-09 2017-03-08 李世军 一种氨基酸神经四肽的合成方法
CN110698557A (zh) * 2019-11-06 2020-01-17 郑州伊美诺生物技术有限公司 Acth突变体、重组蛋白及其应用，以及含有该acth重组蛋白的试剂盒

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446894A3 (en) 2004-10-27 2013-02-20 University Of Denver Adrenocorticotropic hormone analogs and related methods
EP2197465A2 (en) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
CN103724427B (zh) * 2013-11-29 2016-09-28 青岛康原药业有限公司 一种精制促皮质素的方法
US9638703B2 (en) * 2013-12-19 2017-05-02 Universiteit Gent Quantification of glucocorticoids in fish scales as biomarkers for chronic stress
US9688754B2 (en) 2014-02-20 2017-06-27 Alder Biopharmaceuticals, Inc. Anti-ACTH antibodies and use thereof
EP3835319B1 (en) * 2014-12-19 2025-11-19 H. Lundbeck A/S Humanized anti-acth antibodies and use thereof
CN104530219A (zh) * 2014-12-23 2015-04-22 青岛康原药业有限公司 一种精制促皮质素的方法
WO2016168757A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
US11197906B2 (en) 2016-01-22 2021-12-14 On Target Therapeutics Llc Methods of lowering blink reflex for the treatment of dry eye disease
IL302705A (en) * 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
JP7116685B2 (ja) 2016-04-15 2022-08-10 エイチ． ルンドベック アー／エス ヒト化抗ｐａｃａｐ抗体及びそれらの使用
WO2018118115A1 (en) * 2016-12-19 2018-06-28 Eton Pharmaceuticals, Inc. Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
US11338018B2 (en) 2016-12-19 2022-05-24 Harrow Ip, Llc Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
US12433936B2 (en) 2021-04-12 2025-10-07 Nanjing Hanxin Pharmaceutical Technology Co., Ltd. High-purity adrenocorticotropic hormone analogue and a large-scale preparation method thereof
WO2022217395A1 (zh) * 2021-04-12 2022-10-20 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
CN120420414A (zh) * 2024-02-04 2025-08-05 南京汉欣医药科技有限公司 含有人工合成的促皮质素类似物的组合物、其制备方法以及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US4415546A (en) 1981-05-12 1983-11-15 Janakiraman Ramachandran Biologically active analogs of ACTH and radioimmuno assay therefor
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4649191A (en) 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
ATE84420T1 (de) 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5189018A (en) 1991-08-19 1993-02-23 Wayne State University Method for reduction of central nervous system (cns) edema resulting from head and spinal cord trauma
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
JPH08509465A (ja) 1993-01-29 1996-10-08 マイリス メディカル コーポレーション ホルモンの肺内送達
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
DE69519382T3 (de) 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
RU2161502C2 (ru) 1995-06-07 2001-01-10 Элкермес Контролд Терапьютикс, Инк. Композиция для пролонгированного высвобождения гормона роста человека
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
KR20010083070A (ko) 1998-06-26 2001-08-31 실버스타인 아써 에이. 오메가-하이드록시 알데하이드와 아민과의 쉬프 염기부가물의 개선된 제조 방법 및 이를 기재로 하는 물질의조성물
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7229635B2 (en) 2000-04-21 2007-06-12 Indiana University Research And Technology Corporation Pharmacotherapeutic process and composition for central nervous system disorders
WO2002023184A1 (en) 2000-09-13 2002-03-21 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
CA2427146A1 (en) 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
TW200514596A (en) 2003-08-04 2005-05-01 Alza Corp Method and device for enhancing transdermal agent flux
US20050149173A1 (en) 2003-11-10 2005-07-07 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20050147581A1 (en) 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
EP2446894A3 (en) 2004-10-27 2013-02-20 University Of Denver Adrenocorticotropic hormone analogs and related methods

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104277105A (zh) * 2013-07-12 2015-01-14 国家纳米科学中心 抑制β淀粉样蛋白聚集和毒性的多肽抑制剂及其应用
CN104277105B (zh) * 2013-07-12 2017-12-12 国家纳米科学中心 抑制β淀粉样蛋白聚集和毒性的多肽抑制剂及其应用
CN105669856A (zh) * 2016-02-13 2016-06-15 王大勇 一种基因重组长效人促肾上腺皮质激素及其制备方法
CN106478771A (zh) * 2016-10-09 2017-03-08 李世军 一种氨基酸神经四肽的合成方法
CN110698557A (zh) * 2019-11-06 2020-01-17 郑州伊美诺生物技术有限公司 Acth突变体、重组蛋白及其应用，以及含有该acth重组蛋白的试剂盒
CN110698557B (zh) * 2019-11-06 2021-06-18 郑州伊美诺生物技术有限公司 Acth突变体、重组蛋白及其应用，以及含有该acth重组蛋白的试剂盒

Also Published As

Publication number Publication date
KR101150242B1 (ko) 2012-06-13
SG156680A1 (en) 2009-11-26
AU2005305157B2 (en) 2011-09-01
AU2011201914A1 (en) 2011-05-19
WO2006052468A3 (en) 2007-01-11
US20080207518A1 (en) 2008-08-28
NZ554559A (en) 2010-05-28
MX2007004676A (es) 2007-11-14
US20060128620A1 (en) 2006-06-15
CN101189022A (zh) 2008-05-28
IL182818A0 (en) 2007-08-19
CN101189022B (zh) 2012-02-29
US7919577B2 (en) 2011-04-05
US7264314B2 (en) 2007-09-04
EP1814574A2 (en) 2007-08-08
RU2010135499A (ru) 2012-02-27
KR20120050440A (ko) 2012-05-18
WO2006052468A2 (en) 2006-05-18
EP2446894A2 (en) 2012-05-02
EP2446894A3 (en) 2013-02-20
JP2008518026A (ja) 2008-05-29
AU2005305157A1 (en) 2006-05-18
KR101058467B1 (ko) 2011-08-24
US20070197774A1 (en) 2007-08-23
KR20070112761A (ko) 2007-11-27
CA2584221A1 (en) 2006-05-18
KR20100102752A (ko) 2010-09-24
JP2012067099A (ja) 2012-04-05
US20100260681A1 (en) 2010-10-14
RU2407751C2 (ru) 2010-12-27
RU2007119580A (ru) 2008-12-10
EP1814574A4 (en) 2009-08-05
KR101242543B1 (ko) 2013-03-22

Similar Documents

Publication Publication Date Title
CN101189022B (zh) 促肾上腺皮质激素类似物以及相关方法
JPH11507637A (ja) 食欲調節組成物
CN102883735A (zh) 肽的透皮给药
EP0672055A1 (en) Neuropeptide y antagonists
CA2335341A1 (en) Peptide analogues of pacap
KR20080042843A (ko) 치료제의 점막 전달 향상을 위한 밀착 연접 조절 펩티드성분
CN101084009A (zh) Gh促分泌素及其用途
JP6375089B2 (ja) 強力なアゴニスト作用を有する新規なｇｈ−ｒｈ類似体
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
EP3988108A1 (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
JP2010043001A (ja) Ｇｌｐ−１誘導体とその用途
KR100240434B1 (ko) 구조적으로 변형된 혈관작용성 소장 펩티드(vip)의 유도체 및 이를 함유한 제약 조성물
JP6100699B2 (ja) 環状ｃｒｆアンタゴニストペプチド及びその薬学的に許容される塩
HK1148194A (en) Adrenocorticotropic hormone analogs and related methods
US6300471B1 (en) FSH-releasing peptides
CA2293664A1 (en) Fsh-releasing peptides
JP2001526061A (ja) β−リポトロピンおよびその使用
US6407205B1 (en) FSH-releasing peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1148194

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110119

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1148194

Country of ref document: HK